Sign In

Carl Kraus

Founder and Chief Executive Officer at Arrevus

Professional Background

Carl Kraus is a distinguished professional who has dedicated his career to the field of orphan diseases, bringing a wealth of experience as a researcher, regulator, and clinician to the fore. His passion for improving the lives of patients with rare diseases was inspired by personal experiences, notably his father's battle with pancreatic cancer. This deeply personal journey has underpinned his commitment to understanding and enhancing the host immune response, which often becomes compromised in such cases. As the Founder and Chief Executive Officer of Arrevus, Carl has spearheaded initiatives aimed at developing innovative treatments for patients with limited options available to them. His visionary leadership centers on harnessing both established and cutting-edge scientific knowledge to create breakthroughs in the treatment landscape for orphan diseases.

At Arrevus, Carl oversees a variety of pivotal projects that aim to repurpose older therapeutics—such as sodium fusidate for cystic fibrosis—while also exploring novel scientific approaches like leptin antagonism in castration-resistant prostate cancer. His approach is patient-centric, ensuring that the mission of Arrevus is always aligned with improving health outcomes for individuals facing chronic and orphan conditions.

Education and Achievements

Carl Kraus's educational journey began with a Bachelor of Arts in Biology from Washington University in St. Louis, followed by a Doctor of Medicine degree from the same prestigious institution. This rigorous academic background laid a strong foundation for his subsequent career in medicine and research. His impressive credentials are further enhanced by board certifications in both Infectious Diseases and Internal Medicine, highlighting his proficiency and authority in these critical medical fields.

Throughout his career, Carl has held several influential roles that have fortified his reputation as a leader in medical affairs and infectious diseases. His previous positions include serving as the Chief Medical Officer at Nanotherapeutics, Inc., where he contributed to the development of innovative solutions in drug delivery. In addition, Carl held roles at Medscape/WebMD, PRA International, and i3, a UnitedHealth Group Company, where he played a significant role in medical affairs, risk management, and clinical informatics.

A noteworthy part of Carl's professional background is his time as a Medical Officer at the Division of Special Pathogens and Immunologic Drug Products at the U.S. Food and Drug Administration. This role not only showcases his regulatory expertise but also demonstrates his unwavering commitment to public health and patient safety. Furthermore, he served as a Clinical Associate at the National Institute of Allergy and Infectious Diseases, NIH, further solidifying his background in research and clinical development.

Carl's journey began with his clinical residency at University of Chicago Hospitals, providing him with invaluable direct patient care experience that has informed his understanding of the clinical landscape and the challenges faced by patients with rare diseases.

Achievements

Carl Kraus's career is not only marked by his educational and professional credentials but also by his commitment to the advancement of medicine for underrepresented patient populations. His founding of Arrevus exemplifies his proactive approach to addressing unmet medical needs in orphan diseases. Under his stewardship, Arrevus has become a beacon of hope for those suffering from rare conditions, striving to deliver novel and effective treatments based on evidence and innovative science.

The exploration of older drugs for new uses is a testament to Carl’s innovative thinking, showcasing his ability to extract value from existing therapeutics in a manner that expands treatment options for patients. His research endeavors aim not only to improve patient outcomes but also to transform the scientific understanding of disease progression, particularly in the context of orphan diseases.

Moreover, Carl's extensive network and deep knowledge base uniquely position him to influence the future of orphan disease research and treatment. By collaborating with various organizations and experts in the field, he aims to foster an environment where innovative solutions can flourish, ultimately benefiting patients worldwide.

In conclusion, Carl Kraus is more than a seasoned medical professional; he is a compassionate leader dedicated to making a significant difference in the realm of orphan diseases. His educational background, rich professional experiences, and unwavering focus on patient care exemplify his commitment to improving the health and well-being of those facing significant health challenges. Through his leadership at Arrevus and his extensive work in the field, he has become a key player in the quest to offer hope and better health outcomes for patients worldwide.

Related Questions

How did Carl Kraus develop his passion for orphan diseases?
What specific treatments is Carl Kraus currently working on at Arrevus?
How has Carl Kraus's personal experience influenced his professional goals?
In what ways does Carl Kraus envision the future of orphan disease treatments?
What was Carl Kraus's role as Chief Medical Officer at Nanotherapeutics, Inc.?
Carl Kraus
Add to my network

Location

Raleigh-Durham, North Carolina Area